EcoDrugPlus

Endothelin Receptor Type A

Ensembl ID : ENSMAUG00000016677
Gene Symbol: EDNRA
4 Cross references
264 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSMAUG00000014682
Gene Symbol: EDNRB
3 Cross references
264 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSMAUG00000008772
Gene Symbol: EZH2
4 Cross references
222 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSMAUG00000000581
Gene Symbol: EGFR
4 Cross references
285 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSMAUG00000010745
Gene Symbol: EPHX2
4 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSMAUG00000021280
Gene Symbol: ERBB2
2 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSMAUG00000021336
Gene Symbol: ERBB4
4 Cross references
236 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSMAUG00000006785
Gene Symbol: ESR1
2 Cross references
210 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSMAUG00000019282
Gene Symbol: ESR2
3 Cross references
273 Possible Orthologues:

Exportin 1

Ensembl ID : ENSMAUG00000006769
Gene Symbol: XPO1
4 Cross references
304 Possible Orthologues:

Farnesyl Diphosphate Synthetase

Ensembl ID : ENSMAUG00000020872
Gene Symbol: FDPS
1 Cross references
265 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSMAUG00000020139
Gene Symbol: FDFT1
4 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).